Effect of Oral THC Pretreatment on Marijuana Cue-induced Responses in Cannabis Dependent Volunteers

Overview

Journal Drug Alcohol Depend

Publisher Elsevier

Specialty Psychiatry

Date 2015 Mar 2

PMID 25725933

Citations 9

Authors

Leslie H Lundahl

Mark K Greenwald

Affiliations

Soon will be listed here.

Abstract

Background: The current study tested whether oral Δ(9)-tetrahydrocannabinol (THC: 0-, 10-, and 20-mg) pretreatment would attenuate polysensory cue-induced craving for marijuana.

Methods: Cannabis dependent participants (7 males and 7 females, who smoked on average 5.4 ± 1.1 blunts daily) completed 3 experimental sessions (oral THC pretreatment dose; counterbalanced order) using a placebo-controlled within-subject crossover design. During each session, participants completed a baseline evaluation and were first exposed to neutral cues then marijuana cues while physiological measures and subjective ratings of mood, craving, and drug effect were recorded.

Results: Following placebo oral THC pretreatment, marijuana (vs. neutral) cues significantly increased ratings of marijuana craving (desire and urge to use, Marijuana Craving Questionnaire (MCQ)-Compulsivity scale), anxious mood and feeling hungry. Males also reported feeling more "Down" during marijuana cues relative to females. Pretreatment with oral THC (10-mg and/or 20-mg vs. placebo) significantly attenuated marijuana cue-induced increases in craving and anxiety but not hunger. Oral THC attenuation of the cue-induced increase in MCQ-Compulsivity ratings was observed in females only. Oral THC produced statistically (but not clinically) significant increases in heart rate and decreases in diastolic blood pressure, independent of cues.

Conclusions: These marijuana-cue findings replicate earlier results and further demonstrate that oral THC can attenuate selected effects during marijuana multi-cue exposure, and that some of these effects may be sex-related. Results of this study suggest oral THC may be effective for reducing marijuana cue-elicited (conditioned) effects. Further study is needed to determine whether females may selectively benefit from oral THC for this purpose.

Citing Articles

A Secondary Analysis Suggests That Repetitive Transcranial Magnetic Stimulation Applied to the Left Dorsolateral Prefrontal Cortex Reduces Cue-Induced-Craving in Treatment Seeking Participants with Cannabis Use Disorder.

Wong B, Kim B, Singh M, Kim J, McRae-Clark A, Sahlem G medRxiv. 2025; .

PMID: 39867364 PMC: 11759242. DOI: 10.1101/2025.01.16.25320690.

Sex differences in the subjective and reinforcing effects of smoked cannabis.

Lake S, Haney M, Cooper Z Addict Biol. 2023; 28(7):e13301.

PMID: 37369126 PMC: 10300354. DOI: 10.1111/adb.13301.

Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.

Bilbao A, Spanagel R BMC Med. 2022; 20(1):259.

PMID: 35982439 PMC: 9389720. DOI: 10.1186/s12916-022-02459-1.

Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness?.

Tibbo P, McKee K, Meyer J, Crocker C, Aitchison K, Lam R Can J Psychiatry. 2020; 66(2):185-194.

PMID: 32911977 PMC: 7918871. DOI: 10.1177/0706743720945525.

The importance of psychology for shaping legal cannabis regulation.

Borodovsky J, Sofis M, Grucza R, Budney A Exp Clin Psychopharmacol. 2020; 29(1):99-115.

PMID: 32437193 PMC: 7679279. DOI: 10.1037/pha0000362.

References

Berger S, Mickalian J, Reid M, Crawford C, Delucchi K, Carr K . Haloperidol antagonism of cue-elicited cocaine craving. Lancet. 1996; 347(9000):504-8. DOI: 10.1016/s0140-6736(96)91139-3. View

Hart C, Ward A, Haney M, Comer S, Foltin R, Fischman M . Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans. Psychopharmacology (Berl). 2002; 164(4):407-15. DOI: 10.1007/s00213-002-1231-y. View

Franklin T, Napier K, Ehrman R, Gariti P, OBrien C, Childress A . Retrospective study: influence of menstrual cycle on cue-induced cigarette craving. Nicotine Tob Res. 2004; 6(1):171-5. DOI: 10.1080/14622200310001656984. View

McRae-Clark A, Carter R, Price K, Baker N, Thomas S, Saladin M . Stress- and cue-elicited craving and reactivity in marijuana-dependent individuals. Psychopharmacology (Berl). 2011; 218(1):49-58. PMC: 3209966. DOI: 10.1007/s00213-011-2376-3. View

Hersh D, Bauer L, Kranzler H . Carbamazepine and cocaine-cue reactivity. Drug Alcohol Depend. 1995; 39(3):213-21. DOI: 10.1016/0376-8716(95)01165-3. View

Jones R . Marihuana-induced "high": influence of expectation, setting and previous drug experience. Pharmacol Rev. 1971; 23(4):359-69. View

Hart C, Haney M, Ward A, Fischman M, Foltin R . Effects of oral THC maintenance on smoked marijuana self-administration. Drug Alcohol Depend. 2002; 67(3):301-9. DOI: 10.1016/s0376-8716(02)00084-4. View

Ehrman R, Robbins S, Cornish J, Childress A, OBrien C . Failure of ritanserin to block cocaine cue reactivity in humans. Drug Alcohol Depend. 1996; 42(3):167-74. DOI: 10.1016/s0376-8716(96)01278-1. View

Cox L, Tiffany S, Christen A . Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res. 2001; 3(1):7-16. DOI: 10.1080/14622200020032051. View

10.

Nordstrom B, Levin F . Treatment of cannabis use disorders: a review of the literature. Am J Addict. 2007; 16(5):331-42. DOI: 10.1080/10550490701525665. View

11.

Bordnick P, Copp H, Traylor A, Graap K, Carter B, Walton A . Reactivity to cannabis cues in virtual reality environments. J Psychoactive Drugs. 2009; 41(2):105-12. PMC: 4104948. DOI: 10.1080/02791072.2009.10399903. View

12.

Calhoun S, Galloway G, Smith D . Abuse potential of dronabinol (Marinol). J Psychoactive Drugs. 1998; 30(2):187-96. DOI: 10.1080/02791072.1998.10399689. View

13.

Hutchison K, Swift R, Rohsenow D, Monti P, Davidson D, Almeida A . Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology (Berl). 2001; 155(1):27-34. DOI: 10.1007/s002130000629. View

14.

Budney A, Vandrey R, Hughes J, Thostenson J, Bursac Z . Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. J Subst Abuse Treat. 2008; 35(4):362-8. PMC: 4345250. DOI: 10.1016/j.jsat.2008.01.002. View

15.

Stotts A, Dodrill C, Kosten T . Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009; 10(11):1727-40. PMC: 2874458. DOI: 10.1517/14656560903037168. View

16.

Robbins S, Ehrman R, Childress A, OBrien C . Using cue reactivity to screen medications for cocaine abuse: a test of amantadine hydrochloride. Addict Behav. 1992; 17(5):491-9. DOI: 10.1016/0306-4603(92)90009-k. View

17.

Budney A, Vandrey R, Hughes J, Moore B, Bahrenburg B . Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 2006; 86(1):22-9. DOI: 10.1016/j.drugalcdep.2006.04.014. View

18.

Copeland J, Swift W, Rees V . Clinical profile of participants in a brief intervention program for cannabis use disorder. J Subst Abuse Treat. 2001; 20(1):45-52. DOI: 10.1016/s0740-5472(00)00148-3. View

19.

Haney M . The marijuana withdrawal syndrome: diagnosis and treatment. Curr Psychiatry Rep. 2005; 7(5):360-6. DOI: 10.1007/s11920-005-0036-1. View

20.

Childress A, McLellan A, Ehrman R, OBrien C . Classically conditioned responses in opioid and cocaine dependence: a role in relapse?. NIDA Res Monogr. 1988; 84:25-43. View